166 related articles for article (PubMed ID: 36333778)
21. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
[TBL] [Abstract][Full Text] [Related]
22. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
[TBL] [Abstract][Full Text] [Related]
23. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
[TBL] [Abstract][Full Text] [Related]
24. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD
Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378
[TBL] [Abstract][Full Text] [Related]
25. Association between
Zappe K; Pühringer K; Pflug S; Berger D; Böhm A; Spiegl-Kreinecker S; Cichna-Markl M
Cells; 2023 Jun; 12(12):. PubMed ID: 37371109
[TBL] [Abstract][Full Text] [Related]
26. microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
Lizarte Neto FS; Rodrigues AR; Trevisan FA; de Assis Cirino ML; Matias CCMS; Pereira-da-Silva G; Peria FM; Tirapelli DPDC; Carlotti CG
Brain Res; 2019 Oct; 1720():146302. PubMed ID: 31226325
[TBL] [Abstract][Full Text] [Related]
27. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma].
Zhang LY; Ge HJ; Wang LM; Zhao LH; Liu L; Zhang DJ; Cai YN; Lu DH; Piao YS
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):186-191. PubMed ID: 30831643
[No Abstract] [Full Text] [Related]
29. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
30. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
31. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis.
Lee A; Youssef I; Osborn VW; Safdieh J; Becker DJ; Schreiber D
J Clin Neurosci; 2018 May; 51():85-90. PubMed ID: 29483008
[TBL] [Abstract][Full Text] [Related]
32. MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience.
Schlosser S; Wagner S; Mühlisch J; Hasselblatt M; Gerss J; Wolff JE; Frühwald MC
Pediatr Blood Cancer; 2010 Feb; 54(2):228-37. PubMed ID: 19856394
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Wu Q; Berglund AE; Macaulay RJ; Etame AB
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
35. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
36. Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.
Balańa C; Carrato C; Ramírez JL; Cardona AF; Berdiel M; Sánchez JJ; Tarón M; Hostalot C; Musulen E; Ariza A; Rosell R
Clin Transl Oncol; 2011 Sep; 13(9):677-85. PubMed ID: 21865140
[TBL] [Abstract][Full Text] [Related]
37. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
38. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.
Uno M; Oba-Shinjo SM; Camargo AA; Moura RP; Aguiar PH; Cabrera HN; Begnami M; Rosemberg S; Teixeira MJ; Marie SK
Clinics (Sao Paulo); 2011; 66(10):1747-55. PubMed ID: 22012047
[TBL] [Abstract][Full Text] [Related]
39. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
40. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
Zhao H; Wang S; Song C; Zha Y; Li L
World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
